Maykl C. Snabes, MD, PhD, vice president of the clinical development of the Pharmaceuticalses BioSante, will present the retrospect of the key analysis inn LibiGel disentanglement (the gel testosterone) program inn Endocrine Society 90-e Annual Meeting in San Francisco inn the Centre Moscone in Sunday, 15 June, 2008. The Announcement named ” Cardiovascular And Breast Safe Study Libigel In Woman with sex pharmacy pill Disorder of the Desire Hypoactive (HSDD): Project of the analytics And Descriptions of the Endpoints,” - co-authored investigator and consultant inn University America School Medicine, Consultants of the Berry, and M.D. The Cancerous Centre Anderson.

The Conference of the news will be designed in Sunday, 15 June, 2008, during that reporters invited to consider the announcement and discuss LibiGel and described analysis with Dr. Snabes.

BioSante CONDUCTS the safe calculus, in post-woman menopausal with inactive sexual health disorder of the desire (HSDD), on request USA. Food and Administration Medicine. The Request - inn accordance with call to more safe given from Endocrine Society, medical society to professions, which is convergent in endocrine and metabolic infirmity.

Dr. Snabes noted note this preceding installing the analysis. “This clinical criterion to study the long-term effects testosterone in post-woman menopausal, can have ing one of first fecund, cardiovascular operated events, studies pre- approvals were undertake in the absence of clear safe signal.”

BioSante EXPECTS that enrolled and is tested aproximately three thousandth posts-womans menopausal between age fifty and eighty and, which has at small in the same instant one cardiovascular factor of the risk. The medicine online Primary safe result for this test - Each effect of the processing in incidence heartily issue, including cardiovascular confine ary death, heart attack, and blow. Incidence invasive breast cancer is a primary safe endpoint co-, and investigators will also look the favourable withstand breast cancer of the masses and non-invasives. The Patients will are evaluated for hairiness, acne, and speech or reactions of the skin, as well as blood testosterone is justified during each visit of the analysis.

HSDD is CHARACTERIZED low libido and the general mark of the interest in sex. If safe endpoints counter and approves the medicine, LibiGel will become first authorized processing specified in spite of HSDD in menopausal woman. BioSante EXPECTS the approval certain time during 2010 or 2011.

The Feminine earthy dysfunction can arise outright of many reasons, including problems relations, manipulate the pharmaceuticalses of the prescription, disease, or chemical imbalances. HSDD ADDRESSES successfully and successfully with testosterone for many eld though and to date not approved for this use. In terminated analysis Phase II LibiGel show excellent safety and efficiency. However, recently became interested cardiovascular and cancerous exposure to harm bound vulgar form into es medicine, amongst him potential therapy for FSD. The Safe analysis of the Phase III is intended to confirm long-term sanctuary LibiGel’s.

The Operated analysis studies the effect LibiGel in post-woman drugstore online menopausal in dose 300 micrograms per diem covering twelve months. BioSante be SPECIFICALLY focused inn heartily event and incidence breast cancer. After twelve plans of the months BioSante to put or place upon for approval fully New Application Medicine (NDA). requires BioSante to follow the group of the analysis during additional fourty-eight months, after subservience NDA and potential approval two set side by side mate the warmhearted event and breast cancer between group of the processing and corresponding to group of the womans, who get the gel

LibiGel - a gel 1% testosterone that woman enclose as soon as day, in their upper lever. Measured P volume helium carries through skin quickly, from where he delivers the firm dose testosterone on vital current.

Though testosterone thought-out as phallic hormone, he is also discovered in woman on level approaching with their age. The Researchers believe that testosterone will validate, what fall with increasing of the age, can control the feminine physical desire. For Solicitation, woman inn her has about blood testosterone as woman in hits twenty.

Incidence HSDD also increases Ago age and after determined surgical procedures. Aproximately 14% premenopausal womans between age twenty and fourty-nine registered HSDD, in contrast with 26% womans, online pharmacy tablet who surgical have deleted their ovaries. Similarly, incidence HSDD grows before 9% for “by character” menopausal womans. LibiGel is INTENDED to restore the level testosterone in post-womans menopausal on level, which are considered erect to support sound libido.

The Results of the Analysis, what one. carry the above-mentioned safety-deposit box information finally must rest to put the safe enxiety for processing testosterone in woman and tip to go-ahead of the first safe, efficient processing was specifically indicated for HSDD in menopausal woman.